The "Nanjing Antibody Drug Screening and Transformation Engineering Research Center" built this time aims at the difficulties and pain points of key technologies and results transformation in the process of antibody drug research and development and industrialization. It will build and improve the two key platforms of "core technology breakthrough" and "innovation results transformation" to conduct independent localization research on materials and consumables required for the production of biological products, including cell culture medium, protein chromatography medium and virus removal nanofiltration membrane, and carry out results transformation and industrialization development for key innovative antibodies, antibody-drug conjugates and recombinant humanized proteins.

Next, the "Nanjing Antibody Drug Screening and Transformation Engineering Research Center" will further promote the development of biological products and the joint development of upstream and downstream industrial chains, complete the transformation from biosimilars to innovative biological products, develop new antibody drugs with independent intellectual property rights, and ensure the quality and safety of drugs through strict production processes, so as to provide new clinical treatment options for the treatment of major diseases such as cancer and autoimmune diseases.

Nanjing Shunxin Pharmaceutical is a wholly-owned subsidiary of Zhengda Tianqing Pharmaceutical Group. It is mainly engaged in the research, development, production and sales of biological products and innovative drugs. The company will achieve its first biological drug listing in 2023. Currently, it has launched 8 macromolecule drugs such as bevacizumab, trastuzumab, and bemosubizumab. The treatment areas cover tumors, rheumatoid arthritis, ankylosing spondylitis, hemophilia, etc., and the number of macromolecule drugs listed in the domestic pharmaceutical field is significantly ahead. Among them, bemosubizumab is the company's first independently developed Class 1 innovative biological drug, and it is also the first Class 1 innovative biological drug approved for listing in Nanjing this year. Bemosubizumab is an innovative humanized anti-PD-L1 monoclonal antibody with a new sequence. It can prevent PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restore the activity of T cells, and thus enhance the immune response. It is considered to have the potential to treat a variety of tumors [1-4]. This recognition is the second time that Nanjing Shunxin Pharmaceutical has been recognized by the government as a biopharmaceutical technology platform after the Jiangsu Province Innovative Biological Products Engineering Technology Research Center and Nanjing Enterprise Technology Center. It fully affirms the achievements made by Zhengda Tianqing and Nanjing Shunxin Pharmaceutical in the research and development of antibody drugs. The company will take this opportunity to increase R&D investment, deepen exchanges and cooperation with domestic and foreign partners, and jointly promote innovative development in the field of biopharmaceuticals.

https://pharm.jgvogel.cn/c1440469.shtml